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Abstract 
Background: The intestinal stem cells (ISC) modulation and the role of circulating hematopoietic stem cells (HSC) in 
coeliac disease (CD) are poorly understood. Our aim was to investigate the longitudinal modifications in peripheral 
blood HSC traffic and putative ISC density induced by gluten-free diet (GFD) in CD.
Methods: Thirty-one CD patients and 7 controls were enrolled. Circulating CD133+ and CD34+ HSC were measured 
by flow cytometry, at enrolment and after 7 days and 1, 3, 6, 12, and 24 months of GFD. Endoscopy was performed 
at diagnosis and repeated at 6, 12, and 24 months following GFD. We used the Marsh-Oberhuber score to evaluate 
the histological severity of duodenal damage; immunohistochemistry was employed to measure the intraepithelial 
lymphoid infiltrate (IEL, CD3+ lymphoid cells) and the putative ISC compartment (CD133+ and Lgr5+ epithelial cells).
Results: At enrolment, circulating HSCs were significantly increased in CD patients and they further augmented dur-
ing the first week of GFD, but progressively decreased afterwards. CD patients presented with villous atrophy, abun-
dant IEL and rare ISC residing at the crypt base. Upon GFD, IEL progressively decreased, while ISC density increased, 
peaking at 12 months. After 24 months of GFD, all patients were asymptomatic and their duodenal mucosa was 
macroscopically and histologically normal.
Conclusions: In active CD patients, the ISC niche is depleted and there is an increased traffic of circulating HSC ver-
sus non-coeliac subjects. GFD induces a precocious mobilization of circulating HSC, which is followed by the expan-
sion of the local ISC compartment, leading to mucosal healing and clinical remission.
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Background
Coeliac disease (CD) is a chronic inflammatory disease of 
the small bowel, triggered by dietary gluten, in genetically 
susceptible individuals [1]. The diagnosis of CD is based 
on the presence of characteristic lesions in small intesti-
nal biopsy samples (intraepithelial lymphocytosis, elon-
gation of the crypts and villous atrophy). However, since 
villous atrophy is not specific, CD diagnosis also requires 
a positive serology for anti-tissue-transglutaminase 
(atTG) antibodies or anti-endomysial antibodies (EMA), 
and it is confirmed by clinical and/or histological remis-
sion following gluten removal from diet [2]. The clinical 
spectrum of CD is very wide: patients can be asympto-
matic (subclinical), present with trivial or apparently 
unrelated symptoms (non-classical CD), or be severely 
symptomatic, with frank malabsorption symptoms (clas-
sical CD) [3]. Moreover, CD patients might present with 
symptoms of associated autoimmune diseases, such 
as type 1 diabetes and autoimmune thyroiditis [4]. CD 
treatment is based solely on dietary intervention, the 
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so-called gluten-free diet (GFD). With maintenance of a 
GFD, symptoms and serum coeliac antibodies gradually 
disappear, and healing of the intestinal damage typically 
occurs within 24 months of diet [1].
Despite the pathogenic interactions among genetic, 
immunological, and environmental factors in CD have 
been extensively investigated, little is known about intes-
tinal stem cell (ISC) modulation and deregulation during 
the disease course and about the possible contribution of 
circulating bone marrow-derived stem cells to intestinal 
regeneration upon the commencement of a GFD. Aim 
of this study was to assess the circulating hematopoietic 
stem cells (HSC) traffic and putative ISC (CD133+/Lgr5+ 
crypt cell) density in active CD patients and to investigate 
their longitudinal modifications induced by GFD.
Methods
Patients and controls
Patients were enrolled at the time of CD diagnosis, which 
was based upon clinical and serologic findings and sub-
sequently confirmed by histology. After the commence-
ment of a GFD, dietary compliance was established based 
on dietary history and negativization of EMA and atTG.
The control population consisted of non-coeliac sub-
jects, randomly selected from the same geographical area 
of CD patients, with no family history of CD or other 
autoimmune diseases, undergoing an upper endoscopy 
to investigate dyspepsia and/or heartburn or for positive 
family history for gastric cancer and expressing their will 
to participate to the study before the exam. Controls were 
finally enrolled if their esophageal-gastro-duodenosco-
pies resulted negative for coeliac, neoplastic, or inflam-
matory diseases.
Patients and controls were recruited at the Endos-
copy Unit of the Department of Internal Medicine, “A. 
Gemelli” Hospital, Catholic University of Rome. A writ-
ten informed consent was obtained from all participants 
before entering the study protocol. The protocol and the 
consent form had been approved by the local Ethical 
Committee and conformed to the ethical guidelines of 
the Declaration of Helsinki (1975).
Collection of peripheral blood samples and flow cytometry
At baseline, 5 ml of peripheral blood were collected from 
eligible patients and controls. Blood samples from a sub-
set of CD patients were also collected 7 days and 1, 3, 6, 
12, and 24 months after the beginning of the GFD.
All the specimens were collected in heparinized tubes 
and immediately prepared for analysis. The count of 
CD133+ and CD34+ cells co-expressing CD45 was meas-
ured by conventional dual-color flow cytometry, using 
phycoerythrin (PE)-conjugated anti-CD133/2 antibod-
ies (Miltenyi Biotec, Bergisch Gladbach, Germany) or 
PE-conjugated anti-CD34 antibodies [BD Biosciences 
(BD), Mountain View, CA, USA], in combination with 
fluorescein isothiocyanate (FITC)-conjugated anti-CD45 
antibodies (BD). Fluorochrome-conjugated isotype-
matched monoclonal antibodies were used to estab-
lish background fluorescence. Briefly, small aliquots 
of peripheral blood were incubated with the above-
mentioned antibodies for 30  min at 4°C. After red cell 
lysis with the FACS lysing solution (BD), the samples 
were washed twice in PBS (Sigma, St Louis, MO, USA) 
and kept at 4°C until analysis. Samples were acquired 
on a FACS-Calibur® flow cytometer (BD): at least 
5 × 104 events/determination were acquired in list mode 
and the results were analyzed using the Cell Quest® soft-
ware (BD).
The percentage of positive cells among white blood 
cells (WBC) was calculated by subtracting the value of 
the appropriate isotype controls. All the data shown 
in the present report refer to the fraction of CD133+/
CD45+ and CD34+/CD45+ cells that are representative 
of immature hematopoietic cells.
Upper gastrointestinal endoscopy, duodenal sample 
collection, atTG and EMA serology
Upper gastrointestinal endoscopy with duodenal biop-
sies (6 specimens from the distal duodenum) was per-
formed on patients with positive serology for atTG IgA 
and EMA. Once CD diagnosis was histologically con-
firmed, the patients started a GFD; during the follow-up, 
they underwent repeated endoscopies with collection of 
duodenal biopsies at 6, 12, and 24 months following the 
beginning of the GFD. At the same time points, patients 
were clinically evaluated and serum levels of atTG and 
EMA were measured.
Control subjects underwent a single upper gastroin-
testinal endoscopy with duodenal biopsies (6 specimens 
from the distal duodenum); at enrollment, they were also 
clinically evaluated and serum levels of atTG and EMA 
were measured.
Histology and immunohistochemistry
Histological severity of duodenal damage was evalu-
ated according to the Marsh classification modified 
by Oberhuber [5] on 4-µm paraffin sections stained 
with hematoxylin-eosin (H&E): infiltrative lesions with 
intraepithelial lymphocytosis were defined as Marsh I, 
infiltrative/hyperplastic lesions as Marsh II, and partial, 
subtotal, and total villous atrophy as Marsh III (a, b and 
c, respectively).
Lymphoid infiltrate (CD3) and putative ISC density 
(CD133/Lgr5) were assessed by immunohistochem-
istry on 4-µm paraffin sections. Immunohistochemis-
try was performed on deparaffinized sections using the 
Page 3 of 9Piscaglia et al. J Transl Med  (2015) 13:220 
avidin–biotin-peroxidase complex method (ABC-Elite 
Kit; Vector Laboratories, Burlingame, CA, USA). For 
antigen retrieval, paraffin sections were microwave-
treated in 0.01 M citric acid buffer, pH 6.0 (2 cycles for 
5 min each at 750 W), followed by inhibition of endog-
enous peroxidase with 3% H2O2 for 5  min. Then, the 
sections were incubated with the following primary anti-
bodies: anti-CD3 (rabbit polyclonal; dilution 1:50; Dako; 
Glostrup, Denmark); CD133 (rabbit polyclonal; dilution 
1:50; Biocare Medical, Concord, CA) and anti-Lgr5 (anti-
G Protein-Coupled Receptor GPR49, rabbit polyclonal, 
dilution 1:1,000; MBL Int. Corp., Woburn, MA, USA). 
After a 1-h incubation at room temperature, immunode-
tection was performed using goat anti-rabbit secondary 
antibody (Vector Laboratories) and freshly made diamin-
obenzidine as a chromogen.
The number of intraepithelial lymphocytes (IEL) and 
epithelial cell nuclei in a randomly chosen, uninterrupted 
length of surface (villous) epithelium (>500  cells) was 
counted and the mean for the number of IEL/100  cells 
was calculated.
Quantification of ISC was obtained through the count 
of the number of Lgr5+CD133+ epithelial cells per crypt 
from five randomly chosen crypts and the computation 
of the mean value/crypt.
The entire area of the epithelium in each tissue section 
was measured on light microscopy using ×20 objective 
lenses and ×10 eyepiece.
Statistical analysis
Regarding the circulating CD133+ and CD34+ HSC 
counts, the results were expressed as mean  ±  SD. Stu-
dent’s t test for unpaired data was used for the statistical 
analysis.
As for the assessment of villous atrophy, lymphoid infil-
trate and intestinal CD133+ and Lgr5+ cells, statistical 
analysis was performed using the Mann–Whitney U test.
A p value <0.05 was considered statistically significant. 
The data analysis was generated using Microsoft Excel 
software (Microsoft Corporation, Redmond, WA, USA) 
and Real Statistics Resource Pack software (Release 3.5; 




Thirty-one consecutive coeliac patients were enrolled 
from January 2008 to June 2009 (median age 39  years; 
F-to-M ratio = 2.1). Most patients showed minor symp-
toms (i.e., anemia, altered bowel habits, abdominal pain 
and bloating) or symptoms related to associated diseases 
(i.e., thyroiditis, diabetes). All patients presented with 
high titer of serum atTG and EMA; upper endoscopy 
showed in most cases the disappearance or the reduc-
tion of Kerckring folds, associated with absence or hypo-
trophy of the villi at the water immersion technique [6]. 
Histological examination of intestinal biopsies confirmed 
the presence of sub-total or total villous atrophy and IEL 
>25/100 (Marsh III) in all subjects. Patients’ baseline 
characteristics are enlisted in Table 1.
A total of 9 controls undergoing upper endoscopy for 
dyspepsia, heartburn, or family history of gastric can-
cer, matched for sex and age (median age 40 years; F:M 
ratio  =  2) were enrolled immediately before the endo-
scopic examination. Two subjects were subsequently 
excluded from the study, because they had mild gastri-
tis at endoscopy. In the remaining 7 individuals (average 
age 38 years; F-to-M ratio = 2.5), in whom there were no 
pathological endoscopic findings, biopsies were taken 
from the inferior duodenum for histological examination. 
Controls’ baseline characteristics are enlisted in Table 2.
Longitudinal modifications of peripheral blood HSC traffic 
in coeliac patients following a gluten‑free diet
WBC count of all patients and controls was within 
the normal range (4.1–9.8  ×  109/L) at enrolment. The 
absolute number and percentage of both circulating 
CD133+CD45+ and CD34+CD45+ cells were signifi-
cantly higher in coeliac patients versus controls, with no 
differences observed when comparing male and female 
patients (data not shown). In particular, circulating 
CD34+ and CD133+ cell percentage in controls ranged 
from 0.011 to 0.059% (0.028 ±  0.020%) and from 0.008 
to 0.019% (0.011  ±  0.004%), respectively, whereas in 
CD patients, average percentage was 0.166 ±  0.63% for 
CD34+ cells (p < 0.05) and 0.020 ± 0.006% for CD133+ 
cells (p < 0.05).
Following 7  days of GFD, a significant increase of 
circulating HSC traffic was observed in CD patients 
(mean ± SD CD133+ cells 0.745 ± 0.125%; mean ± SD 
CD34+ cells 2.999 ± 0.406%, p < 0.05 versus baseline val-
ues). Afterwards, PB HSC cells progressively decreased 
until reaching the same values as the controls after 
12  months of GFD. Figure  1 depicts the longitudinal 
modifications of circulating HSC traffic in CD patients 
upon starting dietary intervention. Table  3 enlists the 
average and standard deviation of CD133+ and CD34+ 
cell percentages in GFD-treated coeliac patients during 
the follow-up, and the relative p values of the compari-
son with controls and active CD patients at the various 
time-points.
Longitudinal modifications of putative intestinal stem cell 
density in coeliac patients following a gluten‑free diet
At enrolment, all CD patients showed high titers of atTG 
and EMA, sub-total or total villous atrophy (Marsh grade 
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III) and abundant CD3+ IEL at histology (we assumed 
intraepithelial lymphocytosis to be present if >25 IEL/100 
epithelial cells were observed) (Figure  2). All controls had 
normal duodenal aspect at endoscopy and normal histol-
ogy at biopsy (Marsh 0). As expected, upon starting GFD, 
celiac patients experienced a progressive decrease in serum 
atTG and EMA levels and a gradual clinical improvement 
(data not shown). This was mirrored by progressive villous 
regeneration and IEL decrease at histology (Figure 2a). After 
24 months of GFD, all patients were asymptomatic and their 
duodenal mucosa was macroscopically normal; at histol-
ogy, none of the patients had villous atrophy and only 6% of 
them still showed a slight IEL increase (Marsh I) (Figure 2b).
Table 1 Patients’ baseline characteristics
Pts patients, M male, F female, Ab antibodies (atTG and/or EMA), pos positive, CD coeliac disease.
Pt Sex Age Ab Gastrointestinal symptoms Other symptoms Marsh‑Oberhuber
#1 M 34 Pos Diarrhea Dermatitis herpetiformis, anemia IIIc
#2 F 29 Pos Constipation, abdominal bloating None IIIc
#3 M 63 Pos Anemia, dyspepsia None IIIb
#4 M 22 Pos Hypertransaminasemia, diarrhea None IIIc
#5 F 31 Pos None Type 1 diabetes IIIc
#6 M 64 Pos Family history of CD None IIIc
#7 F 57 Pos None Primary biliary cirrhosis, anemia IIIc
#8 F 24 Pos None Anemia IIIb
#9 F 46 Pos Diarrhea, weight loss, malabsorption Osteoporosis, anemia IIIc
#10 F 21 Pos Abdominal pain, constipation Anemia IIIc
#11 F 70 Pos Diarrhea, abdominal bloating Anemia IIIb
#12 F 40 Pos Abdominal discomfort Thyroiditis IIIb
#13 F 50 Pos Constipation, abdominal bloating Thyroiditis IIIa
#14 F 50 Pos Abdominal pain, diarrhea Anemia IIIa
#15 M 38 Pos Abdominal bloating Osteoporosis, anemia IIIc
#16 M 32 Pos Diarrhea None IIIb
#17 M 49 Pos Abdominal pain and bloating None IIIb
#18 F 23 Pos Occasionally altered bowel habits None IIIc
#19 M 26 Pos Diarrhea None IIIc
#20 F 30 Pos Diarrhea Anemia IIIb
#21 F 42 Pos Constipation, abdominal bloating Anemia IIIc
#22 F 43 Pos Family history of CD None IIIa
#23 F 23 Pos None Fatigue IIIc
#24 F 21 Pos Abdominal bloating Rash IIIa
#25 F 28 Pos Dyspepsia Fatigue, anemia IIIc
#26 M 45 Pos None Infertility IIIb
#27 F 46 Pos None Anemia IIIc
#28 F 39 Pos Weight loss Dermatitis herpetiformis, anemia IIIc
#29 F 25 Pos Diarrhea Thyroiditis IIIb
#30 F 46 Pos Abdominal pain, altered bowel habits Type 1 diabetes IIIc
#31 M 55 Pos Diarrhea None IIIc
Table 2 Controls’ baseline characteristics
Ctrls controls, M male, F female, Ab antibodies (atTG and/or EMA), neg negative.
Ctrls Sex Age Ab Gastrointestinal  
symptoms
Marsh‑Oberhuber
#1 F 43 Neg Heartburn 0
#2 F 38 Neg Dyspepsia 0
#3 F 61 Neg Family history of gastric 
cancer
0
#4 M 23 Neg Dyspepsia, epigastric pain 0
#5 F 38 Neg Family history of gastric 
cancer
0
#6 M 21 Neg Heartburn 0
#7 F 44 Neg Dyspepsia 0
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Regarding the putative ISC compartment (CD133+ and 
Lgr5+ intestinal cells), we firstly assessed its cell density 
at the basis of the crypts in the control population: 71% 
of non-coeliac subjects had one CD133+ epithelial cell 
every two crypts and 29% had one CD133+ cell per crypt; 
similar results were obtained for Lgr5+ intestinal cells. 
Therefore, we defined as “normal” a putative ISC density 
of 0.5–1 CD133+ or Lgr5+ cell/crypt (Figure 3a).
On the contrary, in 55% of active CD patients, CD133+ 
and Lgr5+ intestinal cells were less than one every two 
crypts, whereas only 45% had a normal CD133/Lgr5+ 
representation. We defined as “ISC depletion” an ISC 
density <0.5 CD133+/Lgr5+ cell/crypt. Such difference 
in putative ISC density between controls and active CD 
patients was statistically significant (p  <  0.05). Upon 
dietary intervention, the number of CD133+ and Lgr5+ 
epithelial cells significantly increased at 6  months and 
reached a peak at 12  months of GFD, when in some 
patients the putative ISC density was augmented versus 
controls (p < 0.05). We defined a density >1 cell/crypt as 
“ISC amplification”. After 24 months of GFD, the CD133/
Lgr5+ cell density was similar in patients and controls 
(p > 0.05) (Figure 3b–f).
Discussion
The intestinal tract has developed mechanisms to cope 
with the harsh mechanical and chemical conditions to 
which it is exposed, via a highly regulated process of 
self-renewal and turnover [7]. According to the “unify-
ing hypothesis”, all the differentiated epithelial cells of 
the gut derive from a single ISC compartment, which 
resides at the crypt base. From their niche, ISC generate 
transit-amplifying cells that migrate upwards and pro-
gressively lose their proliferative capability and become 
fully differentiated villous epithelial cells. In 1974, two 
distinct theories were formulated regarding the identity 
and location of the ISC: the “+4 position model”, postu-
lating that ISC correspond to slowly cycling label retain-
ing cells (LRC) in +4 position within the crypt; and 
the “stem cell zone model”, that identified the ISC with 
small and rapidly proliferating crypt base columnar cells 
(CBC) [8]. Since the 1970s, several experimental mod-
els have supported the concept of ISC; such studies have 
led to the hypothesis of an ISC hierarchy, organized in 
Figure 1 Longitudinal modifications of circulating HSC traffic in CD 
patients upon starting dietary intervention. a Average percentage of 
circulating CD133+ cells at baseline (T0) and at various time-points 
following gluten removal from diet. b Average percentage of circulat-
ing CD34+ cells at baseline (T0) and at various time-points following 
gluten removal from diet. pts patients, ctrs controls, T0 baseline, T7d 
7 days following gluten removal from diet, T1m, T3m, T6m, T12m and 
T24m 1, 3, 6, 12 and 24 months following gluten removal from diet, 
respectively. *p < 0.05.
Table 3 Circulating CD133+ and CD34+ HSC in GFD-treated coeliac patients during follow-up
The last two rows represent the p values of the comparison between controls and active CD patients at the various time-points.
SD standard deviation, T0 baseline, T7 7 days following gluten removal from diet, T1m, T3m, T6m, T12m and T24m 1, 3, 6, 12 and 24 months following gluten removal 
from diet, respectively, NS non-significant.
Timing T0 T7d T1m T3m T6m T12m T24m
HSC CD133 CD34 CD133 CD34 CD133 CD34 CD133 CD34 CD133 CD34 CD133 CD34 CD133 CD34
Mean % 0.020 0.166 0.745 2.988 0.520 0.626 0.120 0.143 0.091 0.106 0.028 0.042 0.011 0.029
SD % 0.006 0.063 0.125 0.407 0.092 0.093 0.047 0.019 0.024 0.017 0.020 0.008 0.004 0.012
p value versus ctrls <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 <0.05 NS NS NS NS
p value versus T0 CD <0.05 <0.05 <0.05 <0.05 <0.05 NS <0.05 <0.05 NS <0.05 <0.05 <0.05
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two main compartments (quiescent LRC and actively 
cycling CBC), progressively recruited as a result of vari-
ous degrees of damage, in order to ensure an effective 
crypt regeneration [9–11]. Among the candidate mark-
ers for ISC, CD133 and Lgr5 are particularly promising. 
The glycoprotein CD133 (prominin-1) is expressed in 
immature HSC, as well as in other stem and progeni-
tor cells including neural and embryonic stem cells [12, 
13]. CD133 has been used as a colon cancer stem cell 
marker [14] and has also been suggested as a reliable 
marker for ISC [15]. The leucine-rich repeat–contain-
ing G-protein–coupled receptor-5 (Lgr5) is one of the 
Figure 2 Longitudinal modifications of histological severity of duodenal damage in CD patients following GFD. a IEL: at baseline, 52% of CD 
patients presented with IEL >80/100 Epithelial cells (Ep.); 45% with IEL between 50 and 79/100 Ep. and the remaining 3% with IEL between 25 and 
49/100 Ep. Upon GFD commencement, IEL progressively decreased. b Histological severity of duodenal damage evaluated according to the Marsh 
classification modified by Oberhuber (Marsh): at baseline, 58% of patients presented with a Marsh IIIc; 29% with Marsh IIIb and the remaining 13% 
with Marsh IIIa. Upon GFD commencement, all patients experienced a progressive villous regeneration. c and d depict representative CD patients’ 
endoscopic pictures (water immersion technique), while panels e and f correspond to their histological appearance (H&E staining). T0 baseline, 
T1m, T6m, T12m and T24m 1, 6, 12 and 24 months following gluten removal from diet, respectively.
Page 7 of 9Piscaglia et al. J Transl Med  (2015) 13:220 
target genes of the Wnt-pathway and it has recently 
been shown to specifically label stem cells in the mouse 
small intestine [16, 17]. Interestingly, lineage-tracing 
studies showed that some Lgr5+ cells co-express CD133 
and these CD133+ cells can generate the entire intesti-
nal epithelium [14, 18].
Figure 3 Putative intestinal stem cell density in controls and in CD patients. a 71% of non-coeliac subjects had one CD133+ epithelial cell every 
two crypts and 29% had one CD133+ cell per crypt; similar results were obtained for Lgr5+ intestinal cells. Therefore, we defined as “normal” a 
putative ISC density of 0.5–1 CD133+ or Lgr5+ cell/crypt. b At baseline, 55% of CD patients presented with reduced CD133+ and Lgr5+ intestinal 
cells (less than one every two crypts), whereas only 45% had a normal CD133/Lgr5+ representation. We defined as “ISC depletion” an ISC density 
<0.5 CD133+/Lgr5+ cell/crypt. Upon dietary intervention, the number of CD133+ and Lgr5+ epithelial cells significantly increased at 6 months and 
reached a peak at 12 months of GFD, when in some patients the putative ISC density was augmented versus controls. We defined a density >1 cell/
crypt as “ISC amplification”. After 24 months of GFD, the CD133/Lgr5+ cell density was similar in patients and controls. Panels c through f show rep-
resentative immunohistochemistry pictures for CD133+ putative ISC (arrows) in CD patients at baseline (c, higher magnification in d), at 12 months 
(e) and at 24 months (f) of GFD.
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Besides resident ISC, circulating multipotent stem cells 
of bone marrow (BM) origin represent another poten-
tial source for intestinal regeneration. Indeed, over the 
last years, several studies have demonstrated that BM-
derived HSC may participate in gut repair at various lev-
els: by giving rise to ISC, providing supporting elements 
within the ISC niche, and releasing soluble factors that 
promote healing through immune modulation, inhibition 
of apoptosis, and stimulation of resident ISC [19–21].
A better knowledge of ISC function and dysregulation 
in chronic inflammatory bowel diseases might help to 
understand the pathophysiology of such disorders and 
might also offer new insights into the development of 
stem cell-based therapies [11].
In particular, to the best of our knowledge, there is only 
one published study about the potential role of circulat-
ing BM-derived stem cells in CD, by Mastrandrea and 
coworkers, who found an increased traffic of circulating 
CD34+ HSC in active CD patients versus healthy con-
trols [22]. The authors postulated that this phenomenon 
was related to the prevalence of apoptotic versus survival 
programs, a defect shared by chronic inflammatory dis-
eases; in such conditions, HSC might represent a supple-
mentary ISC source.
Indeed, it has been demonstrated that in active CD the 
status of chronic inflammation worsens the epithelial 
layer damage, thus causing activation of NF-κB, which 
leads to a vicious cycle of aberrant immune response, 
mucosal inflammation, increased mucosal permeabil-
ity and impairment of the regenerative potential of the 
intestinal epithelium. Moreover, it has been shown that 
gliadin-derived cytotoxic peptides can induce oxidative 
stress, rearrangement of actin cytoskeleton, impairment 
of epithelial tight-junction assembly, and deregulation of 
the epithelial homeostasis and this might further impair 
the ISC functions [23–25].
Regarding ISC modulation and deregulation in CD, 
it has been observed that ISC differentiation towards 
Paneth cells (PC) and goblet cells may be disturbed in 
active CD. Rubio et  al., found that PC in active CD are 
replaced by lysozyme-producing mucus cells and specu-
lated about an ISC reprogramming, as an antimicrobial 
adaptation to signals generated by pathogenic duodenal 
bacteria [26]. Capuano et al., observed a down-regulation 
of Notch pathway and KLF4 signals in CD patients and a 
reduction of the number of goblet cells in small intestine 
of children with active CD and in those on a GFD, com-
pared to controls [27].
Our results confirm an increased traffic of 
CD133+CD34+ HSC in the peripheral blood of active 
coeliac patients. Additionally, we observed for the first 
time that the putative ISC compartment, represented 
by of CD133+/Lgr5+ crypt epithelial cells, is depleted in 
active CD; this result is in line with the above-mentioned 
theory of impairment of the intestinal regenerative poten-
tial in CD. Interestingly, we found that circulating HSC 
traffic significantly increases in the first week of gluten-
free diet, suggesting that BM-derived stem cells might 
participate in the enteric repair process at the very begin-
ning of the dietary intervention, when the local ISC niche 
is depleted. Afterwards, the circulating HSC progressively 
decrease, together with the immune-mediated intestinal 
damage, and the local ISC compartment expands, leading 
to villous regeneration and clinical remission.
Given the retrospective nature of our study, it is not 
possible to determine whether and to what extent the 
HSCs are contributing directly to the repopulation of 
depleted ISCs. This hypothesis should be tested in animal 
models of CD, for instance upon sex-mismatched HSC 
transplantation [28].
Following a similar approach, BM contribution to the 
intestinal regeneration has been demonstrated in experi-
mental models of inflammatory bowel disease (IBD); this 
evidence supported the rationale for the pharmacological 
mobilization of HSCs in the treatment of IBD [29, 30].
Finally, the dramatic increase in circulating HSC fol-
lowing initiation of GFD is worth speculation. We 
could hypothesize that the circulating BM-derived stem 
cells are migrating to sites of inflammation and being 
consumed in the lesions, and once the inflammation 
is reduced, their numbers increase in the circulation. 
Alternatively, it is possible that gluten removal induces 
the injured gut to release factors involved in HSC mobi-
lization and homing, such as G-CSF and SDF-1 [31]. 
Experimental studies to assess intestinal gene expression 
modifications upon gluten removal would be of help to 
clarify the mechanisms underlying such HSC longitudi-
nal modifications following GFD in CD.
Conclusions
The pathogenic interactions among genetic, immunologi-
cal, and environmental factors in CD have been exten-
sively investigated. On the contrary, little is known about 
ISC modulation and deregulation during the course of 
the disease. In the present study, we observed that the 
putative ISC compartment is depleted in active CD, likely 
due to a status of chronic inflammation, that leads to the 
impairment of the regenerative potential of the intesti-
nal epithelium. Removing the inflammation-inducing 
factor (gluten) allowed for repopulation of the ISC com-
partment to occur. Circulating HSCs might actively con-
tribute to this repopulation process, as suggested by the 
significant increase of HSC traffic at the very beginning 
of the dietary intervention. Afterwards, the circulating 
HSCs progressively decreased and the local ISC compart-
ment expanded, leading to villous regeneration.
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This study sheds some light on the dynamics of intes-
tinal regeneration following GFD in coeliac patients and 
offers novel insights for the development of HSC-based 
treatments against CD. Further studies are required 
to dissect the molecular mechanisms underlying ISC 
impairment in active CD and their expansion upon glu-
ten removal from the diet, and also to clarify the role of 
BM-derived stem cells in intestinal regeneration.
Abbreviations
ISC: intestinal stem cells; HSC: hematopoietic stem cells; CD: coeliac disease; 
GFD: gluten-free diet; IEL: intraepithelial lymphoid infiltrate; atTG: anti-tissue 
transglutaminase antibodies; EMA: anti-endomysial antibodies; PE: phy-
coerythrin; FITC: fluorescein isothiocyanate; WBC: white blood cells; H&E: 
hematoxylin-eosin; LRC: label retaining cells; CBC: crypt base columnar cells; 
BM: bone marrow; PC: Paneth cells; IBD: inflammatory bowel diseases.
Authors’ contributions
ACP and AG provided study concept and design; VC, MC, IAC, GI, FB, LDM 
contributed to the acquisition of data; GB, SR, TC, GC, LML contributed to 
analysis and interpretation of data; ACP drafted the manuscript; AG, LML, LL 
and SR provided critical revision of the manuscript for important intellectual 
content; ACP provided statistical analysis. All authors read and approved the 
final manuscript.
Author details
1 Endoscopy and Gastroenterology Unit, State Hospital, Borgo Maggiore, 
Republic of San Marino. 2 Institute of Internal Medicine and Gastroenterology, 
“A. Gemelli” Hospital, Catholic University, Rome, Italy. 3 Division of Translational 
Medicine, Clinical Research Centre, Sidra Medical and Research Centre, PO 
Box 26999, Burj Doha, 8th Floor, Doha, Qatar. 4 Endoscopy and Gastroen-
terology Unit, “S. Caterina Novella” Hospital, Galatina, Lecce, Italy. 5 Institute 
of Gynecology, “A. Gemelli” Hospital, Catholic University, Rome, Italy. 6 Institute 
of Pathology, “A. Gemelli” Hospital, Catholic University, Rome, Italy. 
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 27 May 2015   Accepted: 30 June 2015
References
 1. Fasano A, Catassi C (2012) Clinical practice. Celiac disease. N Engl J Med 
367:2419–2426
 2. Dewar DH, Ciclitira PJ (2005) Clinical features and diagnosis of celiac 
disease. Gastroenterology 128:S19–S24
 3. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PH et al (2013) 
The Oslo definitions for coeliac disease and related terms. Gut 62:43–52
 4. Di Sabatino A, Corazza GR (2009) Coeliac disease. Lancet 373:1480–1493
 5. Oberhuber G, Granditsch G, Vogelsang H (1999) The histopathology of 
coeliac disease: time for a standardized report scheme for pathologists. 
Eur J Gastroenterol Hepatol 11:1185–1194
 6. Cammarota G, Cesaro P, Martino A, Zuccala G, Cianci R, Nista E et al (2006) 
High accuracy and cost-effectiveness of a biopsy-avoiding endoscopic 
approach in diagnosing coeliac disease. Aliment Pharmacol Ther 
23:61–69
 7. Piscaglia AC, Novi M, Campanale M, Gasbarrini A (2008) Stem cell-based 
therapy in gastroenterology and hepatology. Minim Invasive Ther Allied 
Technol 17:100–118
 8. Barker N, Clevers H (2010) Leucine-rich repeat-containing G-protein-
coupled receptors as markers of adult stem cells. Gastroenterology 
138:1681–1696
 9. Barker N, van Oudenaarden A, Clevers H (2012) Identifying the stem cell 
of the intestinal crypt: strategies and pitfalls. Cell Stem Cell 11:452–460
 10. Scoville DH, Sato T, He XC, Li L (2008) Current view: intestinal stem cells 
and signaling. Gastroenterology 134:849–864
 11. Piscaglia AC (2014) Intestinal stem cells and celiac disease. World J Stem 
Cells 6:213–229
 12. Weigmann A, Corbeil D, Hellwig A, Huttner WB (1997) Prominin, a novel 
microvilli-specific polytopic membrane protein of the apical surface of 
epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial 
cells. Proc Natl Acad Sci USA 94:12425–12430
 13. Kobari L, Giarratana MC, Pflumio F, Izac B, Coulombel L, Douay L (2001) 
CD133+ cell selection is an alternative to CD34+ cell selection for ex vivo 
expansion of hematopoietic stem cells. J Hematother Stem Cell Res 
10:273–281
 14. Zhu L, Gibson P, Currle DS, Tong Y, Richardson RJ, Bayazitov IT et al (2009) 
Prominin 1 marks intestinal stem cells that are susceptible to neoplastic 
transformation. Nature 457:603–607
 15. Montgomery RK, Shivdasani RA (2009) Prominin1 (CD133) as an intestinal 
stem cell marker: promise and nuance. Gastroenterology 136:2051–2054
 16. Barker N, van Es JH, Kuipers J, Kujala P, van den Born M, Cozijnsen M et al 
(2007) Identification of stem cells in small intestine and colon by marker 
gene Lgr5. Nature 449:1003–1007
 17. Barker N, Clevers H (2007) Tracking down the stem cells of the intestine: 
strategies to identify adult stem cells. Gastroenterology 133:1755–1760
 18. Snippert HJ, van Es JH, van den Born M, Begthel H, Stange DE, Barker N 
et al (2009) Prominin-1/CD133 marks stem cells and early progenitors in 
mouse small intestine. Gastroenterology 136(2187–2194):e2181
 19. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R et al 
(2001) Multi-organ, multi-lineage engraftment by a single bone marrow-
derived stem cell. Cell 105:369–377
 20. Brittan M, Wright NA (2004) Stem cell in gastrointestinal structure and 
neoplastic development. Gut 53:899–910
 21. Yan L, Cai C, Li J, Xu S, Chang Q, Li Y et al (2009) Present status and per-
spectives of stem cell-based therapies for gastrointestinal diseases. Stem 
Cell Rev 5:278–282
 22. Mastrandrea F, Semeraro FP, Coradduzza G, Manelli M, Scarcia G, Pez-
zuto F et al (2008) CD34+ hemopoietic precursor and stem cells traffic 
in peripheral blood of celiac patients is significantly increased but not 
directly related to epithelial damage severity. Eur Ann Allergy Clin Immu-
nol 40:90–103
 23. Luciani A, Villella VR, Vasaturo A, Giardino I, Pettoello-Mantovani M, Guido 
S et al (2010) Lysosomal accumulation of gliadin p31–43 peptide induces 
oxidative stress and tissue transglutaminase-mediated PPAR gamma 
downregulation in intestinal epithelial cells and coeliac mucosa. Gut 
59:311–319
 24. Reinke Y, Behrendt M, Schmidt S, Zimmer KP, Naim HY (2011) Impairment 
of protein trafficking by direct interaction of gliadin peptides with actin. 
Exp Cell Res 317:2124–2135
 25. Maiuri MC, De Stefano D, Mele G, Fecarotta S, Greco L, Troncone R et al 
(2003) Nuclear factor kappa B is activated in small intestinal mucosa of 
celiac patients. J Mol Med (Berl) 81:373–379
 26. Rubio CA (2011) Lysozyme-rich mucus metaplasia in duodenal crypts 
supersedes Paneth cells in celiac disease. Virchows Arch 459:339–346
 27. Capuano M, Iaffaldano L, Tinto N, Montanaro D, Capobianco V, Izzo V et al 
(2011) MicroRNA-449a overexpression, reduced NOTCH1 signals and 
scarce goblet cells characterize the small intestine of celiac patients. PLoS 
One 6:e29094
 28. Costes LM, Meresse B, Cerf-Bensussan N, Samsom JN (2015) The role of 
animal models in unravelling therapeutic targets in coeliac disease. Best 
Pract Res Clin Gastroenterol 29:437–450
 29. Martinez-Montiel Mdel P, Gomez-Gomez GJ, Flores AI (2014) Therapy 
with stem cells in inflammatory bowel disease. World J Gastroenterol 
20:1211–1227
 30. Swenson E, Theise N (2010) Stem cell therapeutics: potential in the treat-
ment of inflammatory bowel disease. Clin Exp Gastroenterol 3:1–10
 31. Nervi B, Link DC, DiPersio JF (2006) Cytokines and hematopoietic stem 
cell mobilization. J Cell Biochem 99:690–705
